| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Celiac Disease | 8 | 2019 | 471 | 3.66 | Why? |
| Blastocystis Infections | 4 | 2019 | 12 | 2.51 | Why? |
| Blastocystis | 4 | 2019 | 9 | 2.47 | Why? |
| Iran | 31 | 2021 | 5467 | 1.85 | Why? |
| Helicobacter Infections | 4 | 2018 | 216 | 1.76 | Why? |
| Helicobacter pylori | 4 | 2018 | 262 | 1.73 | Why? |
| Wheat Hypersensitivity | 2 | 2019 | 13 | 1.56 | Why? |
| Bile | 3 | 2019 | 56 | 1.51 | Why? |
| HLA-DQ Antigens | 2 | 2018 | 48 | 1.46 | Why? |
| Biliary Tract Diseases | 2 | 2017 | 60 | 1.28 | Why? |
| Inflammatory Bowel Diseases | 7 | 2019 | 3209 | 1.14 | Why? |
| Stomach Neoplasms | 4 | 2018 | 477 | 1.13 | Why? |
| Feces | 8 | 2019 | 4235 | 1.12 | Why? |
| RNA, Ribosomal, 18S | 3 | 2019 | 68 | 1.11 | Why? |
| Colorectal Neoplasms | 5 | 2019 | 1884 | 1.06 | Why? |
| Interleukins | 2 | 2019 | 762 | 0.99 | Why? |
| Bacteria | 3 | 2019 | 1897 | 0.98 | Why? |
| Bacterial Toxins | 3 | 2019 | 185 | 0.95 | Why? |
| Agricultural Irrigation | 2 | 2019 | 11 | 0.95 | Why? |
| Microsporidiosis | 2 | 2018 | 7 | 0.89 | Why? |
| Cholangiopancreatography, Endoscopic Retrograde | 3 | 2019 | 237 | 0.85 | Why? |
| Toll-Like Receptor 2 | 2 | 2019 | 198 | 0.84 | Why? |
| Intestinal Mucosa | 2 | 2018 | 1046 | 0.82 | Why? |
| Campylobacter jejuni | 1 | 2019 | 27 | 0.80 | Why? |
| Receptors, Interleukin-21 | 1 | 2019 | 6 | 0.80 | Why? |
| Duodenoscopes | 1 | 2019 | 16 | 0.79 | Why? |
| Minisatellite Repeats | 1 | 2019 | 53 | 0.79 | Why? |
| Chemokine CXCL11 | 1 | 2019 | 48 | 0.79 | Why? |
| Salmonella enterica | 1 | 2019 | 39 | 0.78 | Why? |
| Cetuximab | 1 | 2018 | 35 | 0.77 | Why? |
| Adenomatous Polyps | 1 | 2018 | 21 | 0.77 | Why? |
| Blastocystis hominis | 1 | 2018 | 2 | 0.77 | Why? |
| Human Development | 1 | 2018 | 7 | 0.76 | Why? |
| RNA, Ribosomal, 23S | 2 | 2018 | 25 | 0.76 | Why? |
| Encephalitozoon | 1 | 2018 | 2 | 0.76 | Why? |
| Receptors, CXCR3 | 1 | 2019 | 159 | 0.75 | Why? |
| Thioredoxins | 1 | 2018 | 25 | 0.75 | Why? |
| Glutens | 1 | 2019 | 55 | 0.75 | Why? |
| Bacteroides fragilis | 1 | 2018 | 12 | 0.74 | Why? |
| Methanobrevibacter | 1 | 2018 | 15 | 0.73 | Why? |
| Bacteroides Infections | 1 | 2018 | 17 | 0.73 | Why? |
| Oxyuriasis | 1 | 2017 | 3 | 0.73 | Why? |
| Oxyuroidea | 1 | 2017 | 3 | 0.73 | Why? |
| Metalloendopeptidases | 1 | 2018 | 35 | 0.73 | Why? |
| Food Microbiology | 1 | 2019 | 114 | 0.73 | Why? |
| Toll-Like Receptor 9 | 1 | 2018 | 72 | 0.72 | Why? |
| Toll-Like Receptor 4 | 2 | 2019 | 390 | 0.72 | Why? |
| Drug Resistance, Bacterial | 2 | 2018 | 1414 | 0.72 | Why? |
| Bacterial Outer Membrane Proteins | 1 | 2018 | 60 | 0.72 | Why? |
| Enterocytozoon | 1 | 2017 | 2 | 0.71 | Why? |
| Microsporida | 1 | 2017 | 2 | 0.71 | Why? |
| Point Mutation | 2 | 2019 | 481 | 0.70 | Why? |
| Receptors, Retinoic Acid | 1 | 2017 | 39 | 0.70 | Why? |
| Toxoplasmosis | 1 | 2018 | 59 | 0.70 | Why? |
| Ribotyping | 1 | 2017 | 54 | 0.69 | Why? |
| Stomach | 1 | 2018 | 141 | 0.69 | Why? |
| Clarithromycin | 1 | 2018 | 112 | 0.69 | Why? |
| Haplotypes | 2 | 2018 | 853 | 0.69 | Why? |
| Receptor, ErbB-2 | 1 | 2018 | 267 | 0.67 | Why? |
| Host-Parasite Interactions | 1 | 2017 | 112 | 0.66 | Why? |
| Janus Kinase 2 | 1 | 2019 | 218 | 0.66 | Why? |
| DNA, Bacterial | 3 | 2018 | 835 | 0.65 | Why? |
| Enterotoxins | 1 | 2017 | 115 | 0.65 | Why? |
| Genetic Variation | 8 | 2019 | 3919 | 0.64 | Why? |
| Transcriptome | 3 | 2019 | 3466 | 0.64 | Why? |
| Urease | 1 | 2016 | 10 | 0.64 | Why? |
| Escherichia coli Proteins | 1 | 2017 | 168 | 0.63 | Why? |
| Polymorphism, Restriction Fragment Length | 2 | 2014 | 116 | 0.63 | Why? |
| Vegetables | 2 | 2019 | 340 | 0.63 | Why? |
| Tumor Suppressor Proteins | 1 | 2017 | 165 | 0.63 | Why? |
| Toll-Like Receptors | 1 | 2019 | 365 | 0.62 | Why? |
| Interleukin-8 | 2 | 2019 | 964 | 0.59 | Why? |
| Gene Expression Regulation, Bacterial | 1 | 2016 | 143 | 0.59 | Why? |
| Chemokine CXCL10 | 1 | 2019 | 565 | 0.57 | Why? |
| Drug Resistance, Neoplasm | 1 | 2018 | 447 | 0.57 | Why? |
| Systems Biology | 1 | 2017 | 320 | 0.57 | Why? |
| Polymerase Chain Reaction | 8 | 2018 | 6740 | 0.57 | Why? |
| Up-Regulation | 3 | 2019 | 2249 | 0.57 | Why? |
| Helicobacter | 1 | 2014 | 7 | 0.57 | Why? |
| Toll-Like Receptor 7 | 1 | 2018 | 402 | 0.55 | Why? |
| Blood Proteins | 1 | 2018 | 551 | 0.55 | Why? |
| Phylogeny | 6 | 2019 | 13341 | 0.54 | Why? |
| Bacterial Proteins | 3 | 2019 | 1318 | 0.52 | Why? |
| Waste Water | 3 | 2021 | 2185 | 0.52 | Why? |
| Interleukin-17 | 1 | 2018 | 602 | 0.52 | Why? |
| Promoter Regions, Genetic | 1 | 2017 | 823 | 0.51 | Why? |
| Climate | 1 | 2018 | 557 | 0.49 | Why? |
| Bacterial Typing Techniques | 1 | 2014 | 273 | 0.49 | Why? |
| Gastrointestinal Neoplasms | 1 | 2017 | 392 | 0.48 | Why? |
| Immune Tolerance | 1 | 2017 | 608 | 0.48 | Why? |
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 436 | 0.47 | Why? |
| Equipment and Supplies | 1 | 2017 | 440 | 0.47 | Why? |
| DNA Methylation | 1 | 2017 | 688 | 0.47 | Why? |
| Gastroenteritis | 1 | 2017 | 489 | 0.46 | Why? |
| Microbial Sensitivity Tests | 5 | 2019 | 2886 | 0.46 | Why? |
| Hepatitis B, Chronic | 1 | 2019 | 616 | 0.46 | Why? |
| Exodeoxyribonucleases | 1 | 2010 | 17 | 0.45 | Why? |
| Direct Service Costs | 1 | 2010 | 9 | 0.45 | Why? |
| Bile Ducts, Intrahepatic | 1 | 2012 | 68 | 0.45 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2018 | 830 | 0.45 | Why? |
| beta-Lactamases | 1 | 2018 | 759 | 0.45 | Why? |
| Hepatitis B virus | 1 | 2019 | 882 | 0.44 | Why? |
| Case-Control Studies | 13 | 2021 | 17671 | 0.44 | Why? |
| Intestines | 1 | 2017 | 817 | 0.44 | Why? |
| Anti-Bacterial Agents | 3 | 2018 | 10083 | 0.43 | Why? |
| Genotype | 7 | 2019 | 4697 | 0.43 | Why? |
| DNA Repair Enzymes | 1 | 2010 | 33 | 0.43 | Why? |
| DNA, Protozoan | 3 | 2019 | 77 | 0.42 | Why? |
| Cytokines | 7 | 2019 | 15010 | 0.42 | Why? |
| Opportunistic Infections | 1 | 2017 | 602 | 0.42 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 711 | 0.42 | Why? |
| Virulence | 1 | 2017 | 2172 | 0.41 | Why? |
| Constipation | 1 | 2010 | 99 | 0.40 | Why? |
| Escherichia coli | 1 | 2017 | 1547 | 0.39 | Why? |
| Heartburn | 1 | 2009 | 20 | 0.39 | Why? |
| Esophageal pH Monitoring | 1 | 2009 | 33 | 0.39 | Why? |
| Gastrointestinal Tract | 1 | 2018 | 1113 | 0.39 | Why? |
| Cholangiocarcinoma | 1 | 2012 | 186 | 0.38 | Why? |
| Gastrointestinal Microbiome | 3 | 2018 | 1961 | 0.38 | Why? |
| Bile Duct Neoplasms | 1 | 2012 | 172 | 0.38 | Why? |
| Metabolic Syndrome | 1 | 2016 | 810 | 0.37 | Why? |
| Alleles | 3 | 2019 | 1557 | 0.36 | Why? |
| Culture Media, Conditioned | 2 | 2018 | 66 | 0.36 | Why? |
| Clostridium Infections | 1 | 2015 | 595 | 0.36 | Why? |
| Adult | 37 | 2021 | 244371 | 0.35 | Why? |
| Gastroesophageal Reflux | 1 | 2009 | 124 | 0.34 | Why? |
| Staphylococcal Infections | 1 | 2017 | 1099 | 0.34 | Why? |
| Diarrhea | 2 | 2019 | 2743 | 0.34 | Why? |
| Gene Frequency | 3 | 2019 | 1210 | 0.33 | Why? |
| Genetic Markers | 2 | 2019 | 318 | 0.33 | Why? |
| Gene Expression Profiling | 2 | 2018 | 3788 | 0.32 | Why? |
| Inflammation Mediators | 1 | 2018 | 2654 | 0.32 | Why? |
| Biomarkers, Tumor | 4 | 2019 | 1314 | 0.32 | Why? |
| Biomarkers | 3 | 2018 | 23361 | 0.32 | Why? |
| Male | 43 | 2021 | 367725 | 0.31 | Why? |
| Female | 44 | 2021 | 380317 | 0.31 | Why? |
| Humans | 71 | 2021 | 930598 | 0.30 | Why? |
| Glioblastoma | 2 | 2018 | 187 | 0.30 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2019 | 3607 | 0.29 | Why? |
| MicroRNAs | 4 | 2019 | 1787 | 0.29 | Why? |
| Virulence Factors | 2 | 2018 | 338 | 0.28 | Why? |
| Colitis | 2 | 2018 | 266 | 0.28 | Why? |
| Middle Aged | 33 | 2021 | 270681 | 0.28 | Why? |
| Drug Resistance, Multiple, Bacterial | 3 | 2017 | 1115 | 0.28 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2018 | 1969 | 0.27 | Why? |
| Proton Pump Inhibitors | 1 | 2009 | 377 | 0.26 | Why? |
| Intestinal Diseases | 1 | 2006 | 231 | 0.26 | Why? |
| RNA, Long Noncoding | 2 | 2019 | 408 | 0.26 | Why? |
| Adenocarcinoma | 1 | 2010 | 651 | 0.26 | Why? |
| Tuberculosis | 1 | 2019 | 2895 | 0.25 | Why? |
| T-Lymphocytes, Regulatory | 3 | 2018 | 698 | 0.25 | Why? |
| Brain Neoplasms | 2 | 2018 | 669 | 0.22 | Why? |
| Young Adult | 14 | 2021 | 93724 | 0.22 | Why? |
| Multilocus Sequence Typing | 2 | 2019 | 264 | 0.22 | Why? |
| Models, Statistical | 1 | 2018 | 5312 | 0.21 | Why? |
| Aged | 23 | 2021 | 215776 | 0.21 | Why? |
| Farms | 2 | 2019 | 269 | 0.20 | Why? |
| Waste Disposal, Fluid | 1 | 2019 | 60 | 0.20 | Why? |
| HT29 Cells | 1 | 2019 | 108 | 0.20 | Why? |
| Sequence Analysis, DNA | 2 | 2019 | 2830 | 0.20 | Why? |
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 1014 | 0.20 | Why? |
| Toll-Like Receptor 5 | 1 | 2019 | 38 | 0.19 | Why? |
| Campylobacter Infections | 1 | 2019 | 37 | 0.19 | Why? |
| Astrocytes | 2 | 2018 | 298 | 0.19 | Why? |
| Prevalence | 5 | 2019 | 25773 | 0.19 | Why? |
| Caspase 3 | 1 | 2019 | 218 | 0.19 | Why? |
| Spores, Fungal | 1 | 2018 | 23 | 0.19 | Why? |
| Frontal Bone | 1 | 2018 | 1 | 0.19 | Why? |
| PPAR-beta | 1 | 2017 | 1 | 0.19 | Why? |
| Craniosynostoses | 1 | 2018 | 5 | 0.19 | Why? |
| Carcinogenesis | 2 | 2018 | 236 | 0.18 | Why? |
| PPAR delta | 1 | 2017 | 9 | 0.18 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.18 | Why? |
| Toxoplasma | 1 | 2018 | 61 | 0.18 | Why? |
| Apoptosis | 2 | 2019 | 2335 | 0.18 | Why? |
| 14-3-3 Proteins | 1 | 2018 | 55 | 0.18 | Why? |
| Receptors, LDL | 1 | 2017 | 42 | 0.18 | Why? |
| Osteotomy | 1 | 2018 | 30 | 0.18 | Why? |
| Enterotoxigenic Escherichia coli | 1 | 2017 | 15 | 0.18 | Why? |
| Deoxycholic Acid | 1 | 2017 | 17 | 0.18 | Why? |
| Ganciclovir | 1 | 2018 | 97 | 0.18 | Why? |
| Health Care Costs | 1 | 2006 | 1007 | 0.18 | Why? |
| RNA, Fungal | 1 | 2017 | 23 | 0.18 | Why? |
| Choledocholithiasis | 1 | 2017 | 33 | 0.18 | Why? |
| Dependovirus | 1 | 2019 | 272 | 0.18 | Why? |
| Parkinson Disease | 2 | 2021 | 1414 | 0.18 | Why? |
| Tomography, X-Ray Computed | 3 | 2021 | 25144 | 0.18 | Why? |
| Disk Diffusion Antimicrobial Tests | 1 | 2017 | 36 | 0.17 | Why? |
| Bacterial Load | 1 | 2018 | 179 | 0.17 | Why? |
| Genetic Therapy | 2 | 2019 | 409 | 0.17 | Why? |
| Bile Ducts | 1 | 2017 | 84 | 0.17 | Why? |
| Gallbladder | 1 | 2017 | 58 | 0.17 | Why? |
| Denaturing Gradient Gel Electrophoresis | 1 | 2016 | 3 | 0.17 | Why? |
| HIV Protease Inhibitors | 1 | 2020 | 434 | 0.16 | Why? |
| Fibroblast Growth Factors | 1 | 2017 | 119 | 0.16 | Why? |
| Biliary Tract | 1 | 2016 | 21 | 0.16 | Why? |
| Survival Rate | 5 | 2021 | 9206 | 0.16 | Why? |
| Factor Analysis, Statistical | 1 | 2018 | 538 | 0.16 | Why? |
| Genes, Bacterial | 1 | 2017 | 207 | 0.16 | Why? |
| CpG Islands | 1 | 2017 | 230 | 0.16 | Why? |
| Enterococcus faecium | 1 | 2017 | 95 | 0.15 | Why? |
| Gene Expression Regulation | 2 | 2019 | 4020 | 0.15 | Why? |
| RNA, Messenger | 3 | 2019 | 5131 | 0.15 | Why? |
| Microbiological Techniques | 1 | 2018 | 232 | 0.15 | Why? |
| Aged, 80 and over | 10 | 2021 | 88759 | 0.15 | Why? |
| Down-Regulation | 2 | 2018 | 1416 | 0.15 | Why? |
| Irritable Bowel Syndrome | 1 | 2018 | 175 | 0.15 | Why? |
| Intestine, Small | 1 | 2018 | 336 | 0.15 | Why? |
| Life Expectancy | 1 | 2020 | 474 | 0.15 | Why? |
| Adolescent | 10 | 2020 | 86841 | 0.14 | Why? |
| Emigration and Immigration | 1 | 2020 | 501 | 0.14 | Why? |
| Genetic Testing | 1 | 2018 | 395 | 0.14 | Why? |
| Genome, Human | 1 | 2019 | 400 | 0.14 | Why? |
| Genetic Vectors | 2 | 2019 | 1600 | 0.14 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.14 | Why? |
| Drug Resistance, Microbial | 1 | 2019 | 419 | 0.14 | Why? |
| Colonic Neoplasms | 1 | 2018 | 295 | 0.14 | Why? |
| RNA, Ribosomal, 16S | 1 | 2018 | 793 | 0.14 | Why? |
| Interferon-beta | 1 | 2020 | 979 | 0.14 | Why? |
| RNA Interference | 1 | 2017 | 534 | 0.14 | Why? |
| Immunomodulation | 3 | 2018 | 1472 | 0.14 | Why? |
| Bioethics | 1 | 2018 | 253 | 0.13 | Why? |
| Pseudomonas aeruginosa | 1 | 2019 | 652 | 0.13 | Why? |
| Costs and Cost Analysis | 2 | 2010 | 694 | 0.13 | Why? |
| Escherichia coli Infections | 1 | 2017 | 348 | 0.13 | Why? |
| Th2 Cells | 1 | 2017 | 680 | 0.13 | Why? |
| Disease-Free Survival | 1 | 2018 | 1654 | 0.13 | Why? |
| Th17 Cells | 1 | 2018 | 657 | 0.13 | Why? |
| Xanthogranuloma, Juvenile | 1 | 2012 | 6 | 0.12 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2017 | 323 | 0.12 | Why? |
| Morals | 1 | 2018 | 483 | 0.12 | Why? |
| Biopsy | 2 | 2018 | 2811 | 0.12 | Why? |
| Exosomes | 1 | 2019 | 567 | 0.12 | Why? |
| Mice, Inbred C57BL | 3 | 2017 | 5542 | 0.12 | Why? |
| Cluster Analysis | 1 | 2020 | 3001 | 0.12 | Why? |
| Gene Regulatory Networks | 1 | 2017 | 820 | 0.12 | Why? |
| Colonoscopy | 1 | 2018 | 738 | 0.12 | Why? |
| New Zealand | 1 | 2019 | 2073 | 0.12 | Why? |
| Aspartate Aminotransferases | 1 | 2019 | 1394 | 0.11 | Why? |
| Environmental Microbiology | 1 | 2017 | 575 | 0.11 | Why? |
| Asia | 1 | 2019 | 2399 | 0.11 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.11 | Why? |
| Databases, Genetic | 1 | 2017 | 1127 | 0.11 | Why? |
| Base Sequence | 1 | 2019 | 3581 | 0.10 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.10 | Why? |
| Genetic Predisposition to Disease | 2 | 2019 | 4027 | 0.10 | Why? |
| Lymph Nodes | 1 | 2017 | 1060 | 0.10 | Why? |
| Real-Time Polymerase Chain Reaction | 3 | 2019 | 11367 | 0.10 | Why? |
| Hepatitis B | 1 | 2019 | 888 | 0.10 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 1454 | 0.10 | Why? |
| Public Health Practice | 1 | 2018 | 945 | 0.10 | Why? |
| Dendritic Cells | 1 | 2019 | 1330 | 0.10 | Why? |
| Cohort Studies | 3 | 2019 | 36005 | 0.10 | Why? |
| Cells, Cultured | 2 | 2017 | 5835 | 0.10 | Why? |
| Leukocytes, Mononuclear | 1 | 2019 | 2115 | 0.10 | Why? |
| Age Distribution | 1 | 2019 | 3567 | 0.09 | Why? |
| Predictive Value of Tests | 2 | 2018 | 9537 | 0.09 | Why? |
| Manometry | 1 | 2009 | 91 | 0.09 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2019 | 2483 | 0.09 | Why? |
| Craniopharyngioma | 1 | 2008 | 11 | 0.09 | Why? |
| Tumor Cells, Cultured | 2 | 2018 | 254 | 0.09 | Why? |
| Dextran Sulfate | 2 | 2018 | 54 | 0.09 | Why? |
| Sensitivity and Specificity | 2 | 2020 | 22971 | 0.09 | Why? |
| Mass Screening | 2 | 2018 | 8005 | 0.09 | Why? |
| Neurosurgery | 1 | 2021 | 1585 | 0.09 | Why? |
| Supine Position | 1 | 2009 | 158 | 0.09 | Why? |
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 907 | 0.09 | Why? |
| Academic Medical Centers | 1 | 2021 | 3088 | 0.09 | Why? |
| Mutation | 2 | 2018 | 12376 | 0.09 | Why? |
| Reconstructive Surgical Procedures | 1 | 2018 | 860 | 0.09 | Why? |
| Inflammation | 3 | 2020 | 13255 | 0.08 | Why? |
| Brachytherapy | 1 | 2008 | 93 | 0.08 | Why? |
| Epithelial Cells | 1 | 2019 | 3508 | 0.08 | Why? |
| Early Detection of Cancer | 1 | 2018 | 1956 | 0.08 | Why? |
| Cysts | 1 | 2008 | 94 | 0.08 | Why? |
| Socioeconomic Factors | 2 | 2019 | 8495 | 0.08 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.08 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.08 | Why? |
| Child | 5 | 2019 | 70012 | 0.08 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.08 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.08 | Why? |
| Pituitary Neoplasms | 1 | 2008 | 130 | 0.08 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Computational Biology | 2 | 2018 | 4514 | 0.07 | Why? |
| Disinfection | 1 | 2019 | 2912 | 0.07 | Why? |
| Australia | 1 | 2019 | 6306 | 0.07 | Why? |
| Animals | 7 | 2019 | 78931 | 0.07 | Why? |
| Caregivers | 1 | 2020 | 3112 | 0.07 | Why? |
| Mutation, Missense | 1 | 2010 | 863 | 0.07 | Why? |
| Neoplasm Staging | 1 | 2012 | 1999 | 0.07 | Why? |
| Brain | 2 | 2018 | 5133 | 0.07 | Why? |
| Liver Transplantation | 1 | 2020 | 2864 | 0.07 | Why? |
| Radiography, Thoracic | 1 | 2021 | 5486 | 0.07 | Why? |
| Patient Admission | 1 | 2021 | 5250 | 0.07 | Why? |
| Time-to-Treatment | 1 | 2021 | 5883 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.07 | Why? |
| Europe | 1 | 2020 | 12702 | 0.06 | Why? |
| Demography | 1 | 2010 | 1660 | 0.06 | Why? |
| Amino Acid Substitution | 1 | 2010 | 1706 | 0.06 | Why? |
| Elective Surgical Procedures | 1 | 2021 | 5338 | 0.06 | Why? |
| Survival Analysis | 1 | 2016 | 7592 | 0.06 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.06 | Why? |
| Treatment Failure | 1 | 2009 | 2106 | 0.06 | Why? |
| Disease Susceptibility | 1 | 2015 | 4002 | 0.06 | Why? |
| Time Factors | 2 | 2019 | 31397 | 0.05 | Why? |
| Cross-Sectional Studies | 4 | 2020 | 53120 | 0.05 | Why? |
| Hospitals | 2 | 2017 | 11793 | 0.05 | Why? |
| Prognosis | 4 | 2021 | 32490 | 0.05 | Why? |
| Incidence | 2 | 2020 | 25622 | 0.05 | Why? |
| Glasgow Coma Scale | 1 | 2021 | 249 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Referral and Consultation | 2 | 2020 | 4816 | 0.05 | Why? |
| Brain Diseases | 1 | 2012 | 1463 | 0.05 | Why? |
| Pharmaceutical Vehicles | 1 | 2019 | 4 | 0.05 | Why? |
| Immunity, Innate | 1 | 2018 | 6570 | 0.05 | Why? |
| Astrocytoma | 1 | 2018 | 29 | 0.05 | Why? |
| Thymidine Kinase | 1 | 2018 | 11 | 0.05 | Why? |
| Gap Junctions | 1 | 2018 | 18 | 0.05 | Why? |
| Connexin 43 | 1 | 2018 | 37 | 0.05 | Why? |
| Cell Line, Tumor | 2 | 2018 | 3608 | 0.05 | Why? |
| Antiparkinson Agents | 1 | 2020 | 125 | 0.05 | Why? |
| Bystander Effect | 1 | 2018 | 68 | 0.05 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.05 | Why? |
| Aspartic Acid | 1 | 2018 | 76 | 0.05 | Why? |
| Creatine | 1 | 2018 | 66 | 0.05 | Why? |
| Infant | 2 | 2019 | 30274 | 0.05 | Why? |
| Asymptomatic Infections | 1 | 2018 | 7218 | 0.05 | Why? |
| Activating Transcription Factor 4 | 1 | 2017 | 14 | 0.05 | Why? |
| Microscopy, Atomic Force | 1 | 2019 | 118 | 0.05 | Why? |
| Philosophy, Medical | 1 | 2018 | 29 | 0.05 | Why? |
| Choline | 1 | 2018 | 77 | 0.05 | Why? |
| Bone Transplantation | 1 | 2018 | 38 | 0.04 | Why? |
| Mice | 4 | 2019 | 21357 | 0.04 | Why? |
| Health Policy | 1 | 2018 | 6242 | 0.04 | Why? |
| Microscopy, Electron, Scanning | 1 | 2019 | 221 | 0.04 | Why? |
| Coculture Techniques | 1 | 2018 | 258 | 0.04 | Why? |
| Orbit | 1 | 2018 | 51 | 0.04 | Why? |
| Gene Knockdown Techniques | 1 | 2018 | 347 | 0.04 | Why? |
| Immunoglobulin G | 2 | 2020 | 21571 | 0.04 | Why? |
| Child, Preschool | 2 | 2019 | 36283 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.04 | Why? |
| Electrophoresis, Gel, Pulsed-Field | 1 | 2017 | 78 | 0.04 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.04 | Why? |
| eIF-2 Kinase | 1 | 2017 | 117 | 0.04 | Why? |
| Primary Cell Culture | 1 | 2018 | 501 | 0.04 | Why? |
| Genes, Reporter | 1 | 2018 | 472 | 0.04 | Why? |
| Moral Obligations | 1 | 2018 | 125 | 0.04 | Why? |
| Stroke | 1 | 2020 | 8839 | 0.04 | Why? |
| Lymphatic Metastasis | 1 | 2019 | 537 | 0.04 | Why? |
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 317 | 0.04 | Why? |
| Antibodies, Neutralizing | 2 | 2020 | 25288 | 0.04 | Why? |
| Olfactory Mucosa | 1 | 2018 | 372 | 0.04 | Why? |
| Herpesvirus 1, Human | 1 | 2018 | 286 | 0.04 | Why? |
| Reoperation | 1 | 2018 | 544 | 0.04 | Why? |
| Bioethical Issues | 1 | 2018 | 233 | 0.04 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.03 | Why? |
| Anxiety | 1 | 2020 | 17311 | 0.03 | Why? |
| Overweight | 1 | 2020 | 916 | 0.03 | Why? |
| RNA, Small Interfering | 1 | 2018 | 817 | 0.03 | Why? |
| Tertiary Care Centers | 1 | 2012 | 8248 | 0.03 | Why? |
| Outpatients | 1 | 2006 | 3417 | 0.03 | Why? |
| Magnetic Resonance Spectroscopy | 1 | 2018 | 881 | 0.03 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.03 | Why? |
| Drug Carriers | 1 | 2019 | 590 | 0.03 | Why? |
| Colon | 1 | 2018 | 669 | 0.03 | Why? |
| Vinblastine | 1 | 2012 | 48 | 0.03 | Why? |
| Pandemics | 7 | 2021 | 389249 | 0.03 | Why? |
| Evidence-Based Practice | 1 | 2018 | 693 | 0.03 | Why? |
| Health Care Reform | 1 | 2018 | 409 | 0.03 | Why? |
| Feasibility Studies | 1 | 2021 | 3467 | 0.03 | Why? |
| Community Participation | 1 | 2018 | 605 | 0.03 | Why? |
| Mitochondria | 1 | 2018 | 857 | 0.03 | Why? |
| Primary Prevention | 1 | 2018 | 778 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2020 | 51949 | 0.03 | Why? |
| Social Justice | 1 | 2018 | 706 | 0.03 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.03 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.03 | Why? |
| Disease Models, Animal | 2 | 2018 | 10998 | 0.02 | Why? |
| Neurosurgical Procedures | 1 | 2021 | 1738 | 0.02 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.02 | Why? |
| Kidney Diseases | 1 | 2020 | 1434 | 0.02 | Why? |
| Phosphorus Radioisotopes | 1 | 2008 | 2 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2019 | 2742 | 0.02 | Why? |
| Prednisolone | 1 | 2012 | 443 | 0.02 | Why? |
| Stereotaxic Techniques | 1 | 2008 | 19 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2021 | 6543 | 0.02 | Why? |
| Lymphopenia | 1 | 2020 | 2669 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2019 | 5814 | 0.02 | Why? |
| Methotrexate | 1 | 2012 | 471 | 0.02 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.02 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.02 | Why? |
| Software | 1 | 2018 | 2501 | 0.02 | Why? |
| Mesenchymal Stem Cell Transplantation | 1 | 2018 | 1322 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Disaster Planning | 1 | 2018 | 1680 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.02 | Why? |
| Delivery of Health Care | 1 | 2010 | 15909 | 0.02 | Why? |
| Radiography | 1 | 2012 | 1576 | 0.02 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.02 | Why? |
| Health Care Rationing | 1 | 2018 | 2558 | 0.02 | Why? |
| Liver | 1 | 2017 | 4007 | 0.02 | Why? |
| Cell Line | 1 | 2019 | 12040 | 0.02 | Why? |
| Postoperative Complications | 1 | 2021 | 5861 | 0.02 | Why? |
| Treatment Outcome | 3 | 2018 | 51732 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2019 | 17020 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2006 | 43792 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2020 | 8207 | 0.01 | Why? |
| Drug Therapy, Combination | 1 | 2012 | 7268 | 0.01 | Why? |
| Antineoplastic Agents | 1 | 2012 | 3550 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.01 | Why? |
| Neoplasms | 1 | 2020 | 17251 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |
| Intensive Care Units | 1 | 2017 | 29594 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |